Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Update of sleep alterations in depression.

Medina AB, Lechuga DA, Escandón OS, Moctezuma JV.

Sleep Sci. 2014 Sep;7(3):165-9. doi: 10.1016/j.slsci.2014.09.015. Epub 2014 Sep 27. Review.

2.

Major depressive disorder: mechanism-based prescribing for personalized medicine.

Saltiel PF, Silvershein DI.

Neuropsychiatr Dis Treat. 2015 Mar 31;11:875-88. doi: 10.2147/NDT.S73261. eCollection 2015. Review.

3.

Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2).

Matza LS, Murray LT, Phillips GA, Konechnik TJ, Dennehy EB, Bush EN, Revicki DA.

Patient. 2015 Oct;8(5):433-43. doi: 10.1007/s40271-014-0107-7.

4.

Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?

Greer TL, Sunderajan P, Grannemann BD, Kurian BT, Trivedi MH.

Depress Res Treat. 2014;2014:627863. doi: 10.1155/2014/627863. Epub 2014 Jan 19.

5.

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV.

J Clin Psychopharmacol. 2014 Feb;34(1):47-56. doi: 10.1097/JCP.0000000000000060.

6.

Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.

Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P.

J Psychosom Res. 2013 Jan;74(1):57-63. doi: 10.1016/j.jpsychores.2012.10.012. Epub 2012 Nov 21.

7.

Adipocytokine signaling is altered in Flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression.

Wilhelm CJ, Choi D, Huckans M, Manthe L, Loftis JM.

Pharmacol Biochem Behav. 2013 Jan;103(3):643-51. doi: 10.1016/j.pbb.2012.11.001. Epub 2012 Nov 12.

8.

The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition.

Matza LS, Wyrwich KW, Phillips GA, Murray LT, Malley KG, Revicki DA.

Qual Life Res. 2013 Mar;22(2):351-60. doi: 10.1007/s11136-012-0142-6. Epub 2012 Mar 9.

9.

The noradrenergic symptom cluster: clinical expression and neuropharmacology.

Blier P, Briley M.

Neuropsychiatr Dis Treat. 2011;7(Suppl 1):15-20. doi: 10.2147/NDT.S19613. Epub 2011 Jun 3.

10.

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication.

McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, Cook I, Morris D, Warden D, Rush AJ.

J Clin Psychopharmacol. 2011 Apr;31(2):180-6. doi: 10.1097/JCP.0b013e31820ebd2c. Erratum in: J Clin Psychopharmacol. 2013 Dec;33(6):765.

11.

Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.

Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, Dicke A, Friedman J.

Am J Geriatr Psychiatry. 2011 Mar;19(3):222-9. doi: 10.1097/JGP.0b013e3181e448f7.

Items per page

Supplemental Content

Write to the Help Desk